Nabriva Therapeutics Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nabriva Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Nabriva Therapeutics stock.
View analyst ratings for Nabriva Therapeutics or view top-rated stocks.

Wall Street analysts have given Nabriva Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Nabriva Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Nabriva Therapeutics saw a drop in short interest in the month of August. As of August 31st, there was short interest totaling 1,540,000 shares, a drop of 31.3% from the August 15th total of 2,240,000 shares. Based on an average trading volume of 1,180,000 shares, the days-to-cover ratio is currently 1.3 days. Approximately 3.2% of the company's shares are sold short.
View Nabriva Therapeutics' Short Interest.

Nabriva Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Nabriva Therapeutics.

Nabriva Therapeutics plc (NASDAQ:NBRV) released its quarterly earnings results on Thursday, August, 5th. The biotechnology company reported ($0.29) EPS for the quarter, topping the Zacks' consensus estimate of ($0.35) by $0.06. The biotechnology company had revenue of $8.24 million for the quarter, compared to the consensus estimate of $5.99 million. Nabriva Therapeutics had a negative trailing twelve-month return on equity of 63.27% and a negative net margin of 210.82%.
View Nabriva Therapeutics' earnings history.

Nabriva Therapeutics' stock was trading at $1.21 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NBRV stock has decreased by 7.4% and is now trading at $1.12.
View which stocks have been most impacted by COVID-19.

2 Wall Street analysts have issued 1-year price targets for Nabriva Therapeutics' shares. Their forecasts range from $6.00 to $6.00. On average, they expect Nabriva Therapeutics' share price to reach $6.00 in the next twelve months. This suggests a possible upside of 435.7% from the stock's current price.
View analysts' price targets for Nabriva Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Nabriva Therapeutics include Nuvation Bio (NUVB), Harmony Biosciences (HRMY), Rocket Pharmaceuticals (RCKT), Indivior (INVVY), Myovant Sciences (MYOV), Organogenesis (ORGO), Ironwood Pharmaceuticals (IRWD), Amarin (AMRN), Revance Therapeutics (RVNC), Xencor (XNCR), ADC Therapeutics (ADCT), Cassava Sciences (SAVA), Deciphera Pharmaceuticals (DCPH), Trillium Therapeutics (TRIL) and NGM Biopharmaceuticals (NGM).
View all of NBRV's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Nabriva Therapeutics investors own include SCYNEXIS (SCYX), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Dynavax Technologies (DVAX), Acasti Pharma (ACST), Amarin (AMRN), AcelRx Pharmaceuticals (ACRX), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and Heat Biologics (HTBX).

Nabriva Therapeutics trades on the NASDAQ under the ticker symbol "NBRV."

Nabriva Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.18%), State Street Corp (0.04%), Morgan Stanley (0.02%), Morgan Stanley (0.02%), Susquehanna International Group LLP (0.00%) and Parametric Portfolio Associates LLC (0.01%). Company insiders that own Nabriva Therapeutics stock include Colin Md Broom, Stephen W Webster and Theodore R Schroeder.
View institutional ownership trends for Nabriva Therapeutics.

NBRV stock was sold by a variety of institutional investors in the last quarter, including Susquehanna International Group LLP, and Citadel Advisors LLC.
View insider buying and selling activity for Nabriva Therapeutics or view top insider-selling stocks.

NBRV stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Morgan Stanley, Morgan Stanley, State Street Corp, HAP Trading LLC, Millennium Management LLC, Parametric Portfolio Associates LLC, and Clear Creek Financial Management LLC.
View insider buying and selling activity for Nabriva Therapeutics or or view top insider-buying stocks.

Shares of NBRV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NBRV stock can currently be purchased for approximately $1.12.

Nabriva Therapeutics has a market capitalization of $557.08 million and generates $5.03 million in revenue each year. The biotechnology company earns $-69,480,000.00 in net income (profit) each year or ($5.20) on an earnings per share basis.

Nabriva Therapeutics employs 72 workers across the globe.

The official website for Nabriva Therapeutics is www.nabriva.com.

Nabriva Therapeutics is headquartered at 25-28 NORTH WALL QUAY IFSC, DUBLIN L2, 19406.

Nabriva Therapeutics' mailing address is 25-28 NORTH WALL QUAY IFSC, DUBLIN L2, 19406. The biotechnology company can be reached via phone at (531) 649-2000 or via email at [email protected].